Medtech Has Hope For A Solid Recovery Later In 2021
Medtech Is Still An Attractive Market Says Jefferies Healthcare
Executive Summary
Delivering innovation is still the driving force for medtechs intent on growing in the market, regardless of COVID-19, the disruptive effects of which have intensified with the appearance of new variants, says Jefferies Healthcare equity analyst Raj Denhoy.
You may also be interested in...
Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.
Singapore Prepares UDI System, Malaysia Seeks Regulatory Improvements And Indonesia Adjusts To Changing Environment
Medtech industry representatives from ASEANMed member economies, notably Singapore, Malaysia and Indonesia, provided regulatory updates at the February Asia Regulatory Roundtable. These roundtables are organized by the ARQon consultancy and the Asia Regulatory Professional Association (ARPA). They are sponsored by Medtech Insight.
VC View: Riding The Waves Of Asia’s Healthtech Explosion
Asia continues to gain attention for its healthtech innovation and adoption activity, and VC investors have seen the merits of a maintaining a focus on this newly emerging regional innovation hotspot, regardless of the pandemic.
Need a specific report? 1000+ reports available
Buy Reports